144 related articles for article (PubMed ID: 20392896)
1. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.
Funke C; Farr M; Werner B; Dittmann S; Überla K; Piper C; Niehaus K; Horstkotte D
J Gen Virol; 2010 Aug; 91(Pt 8):1959-1970. PubMed ID: 20392896
[TBL] [Abstract][Full Text] [Related]
2. Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells.
Werner B; Dittmann S; Funke C; Überla K; Piper C; Niehaus K; Horstkotte D; Farr M
Inflamm Res; 2014 Apr; 63(4):267-76. PubMed ID: 24316867
[TBL] [Abstract][Full Text] [Related]
3. Treatment of coxsackievirus-B3-infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury.
Dörner A; Grunert HP; Lindig V; Chandrasekharan K; Fechner H; Knowlton KU; Isik A; Pauschinger M; Zeichhardt H; Schultheiss HP
J Mol Med (Berl); 2006 Oct; 84(10):842-51. PubMed ID: 16924471
[TBL] [Abstract][Full Text] [Related]
4. Expression of coxsackievirus and adenovirus receptor (CAR)-Fc fusion protein in Pichia pastoris and characterization of its anti-coxsackievirus activity.
Zhang K; Yu H; Xie W; Xu Z; Zhou S; Huang C; Sheng H; He X; Xiong J; Qian G
J Biotechnol; 2013 Apr; 164(4):461-8. PubMed ID: 23376619
[TBL] [Abstract][Full Text] [Related]
5. The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.
Pinkert S; Röger C; Kurreck J; Bergelson JM; Fechner H
J Virol; 2016 Jun; 90(12):5601-5610. PubMed ID: 27030267
[TBL] [Abstract][Full Text] [Related]
6. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
[TBL] [Abstract][Full Text] [Related]
8. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
Stein EA; Pinkert S; Becher PM; Geisler A; Zeichhardt H; Klopfleisch R; Poller W; Tschöpe C; Lassner D; Fechner H; Kurreck J
J Infect Dis; 2015 Feb; 211(4):613-22. PubMed ID: 25193982
[TBL] [Abstract][Full Text] [Related]
9. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
Shafren DR; Williams DT; Barry RD
J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
11. Interspecies differences in virus uptake versus cardiac function of the coxsackievirus and adenovirus receptor.
Freiberg F; Sauter M; Pinkert S; Govindarajan T; Kaldrack J; Thakkar M; Fechner H; Klingel K; Gotthardt M
J Virol; 2014 Jul; 88(13):7345-56. PubMed ID: 24741103
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
13. Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
Pinkert S; Kopp A; Brückner V; Fechner H; Beling A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669334
[TBL] [Abstract][Full Text] [Related]
14. Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus.
Pinkert S; Dieringer B; Diedrich S; Zeichhardt H; Kurreck J; Fechner H
Antiviral Res; 2016 Dec; 136():1-8. PubMed ID: 27773751
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor.
Sharma M; Mishra B; Saikia UN; Bahl A; Ratho RK
Indian J Med Res; 2017 Oct; 146(4):520-527. PubMed ID: 29434067
[TBL] [Abstract][Full Text] [Related]
16. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
17. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis.
Li M; Yan K; Wei L; Yang J; Lu C; Xiong F; Zheng C; Xu W
Antiviral Res; 2015 Nov; 123():50-61. PubMed ID: 26343012
[TBL] [Abstract][Full Text] [Related]
18.
Lee YG; Park JH; Jeon ES; Kim JH; Lim BK
J Microbiol Biotechnol; 2016 Nov; 26(11):2012-2018. PubMed ID: 27558433
[TBL] [Abstract][Full Text] [Related]
19. Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis.
Marchant D; Dou Y; Luo H; Garmaroudi FS; McDonough JE; Si X; Walker E; Luo Z; Arner A; Hegele RG; Laher I; McManus BM
Circ Res; 2009 Mar; 104(6):813-21. PubMed ID: 19213955
[TBL] [Abstract][Full Text] [Related]
20. Coxsackie B viruses use multiple receptors to infect human cardiac cells.
Orthopoulos G; Triantafilou K; Triantafilou M
J Med Virol; 2004 Oct; 74(2):291-9. PubMed ID: 15332279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
